The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor
As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies. In recent years, the incidence of cervical cancer, especially in young women significantly increased; ovarian cancer, although the incidence of malignant tumors in the female reproductive system ranked second, but its mortality rate already in the first place; and the morbidity and mortality of endometrial cancer is also rising.
The key to gynecologic malignancies is how to early diagnose and treat. With the advancement of science and technology, such as molecular biology techniques widely used in the medical field, early diagnosis, proper treatment and other aspects in gynecologic malignancies is expected to achieve a breakthrough. Genome-wide scan strategy, making the whole genome for linkage analysis for gynecological malignancies possible. Therefore, the investigators intend to find specific mutations to provide a new early screening approach for gynecological malignancies, which in later result in early diagnosis and specific treatment for gynecological malignant tumors.
研究概览
地位
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
Chongqing
-
Chongqing、Chongqing、中国、400038
- Department of Obstetrics and Gynaecology, Southwest Hospital, Third Military
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Female aging from 16 to 75-year old;
- Preoperative diagnosis of gynecologic malignancies;
- Have the ability to comply with Research programs;
- Voluntarily participate in the study and signed an informed consent form
Exclusion Criteria:
- The cases do not meet the inclusion criteria should be removed from,indicating the reason for excluding.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
---|
experiment group
patients with cervical cancer, endometrial cancers or ovary cancer
|
control group
postmenopausal women with benign tumor
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Gene mutation from species of cervical cancer, endometrial cancers and ovary cancer
大体时间:4 years
|
We expect to found spcific DNA mutation in the species (peripheral blood, liquid Pap smear and cancer tissue) from cervical cancer, endometrial cancers and ovary.
|
4 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
the difference between detection sensitivity
大体时间:4 years
|
Comparing sensiitivity of the three kinds of samples on early detection of gynecologic malignancies
|
4 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 001 (NavyGHB)
- fck001 (注册表标识符:ZLiang)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.